Clinical Trial Update: Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a trial evaluating WEF-001 as monotherapy for safety, tolerability, pharmacokinetics, and preliminary efficacy in advanced KRAS-mutant solid tumors; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• WEF-001

Snippet

Sponsor: Auricula Biosciences Inc. | Conditions: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING